| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Nanjing Well Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.37 |
| 52 Week High | CN¥29.80 |
| 52 Week Low | CN¥17.65 |
| Beta | 0.37 |
| 11 Month Change | -12.58% |
| 3 Month Change | -9.14% |
| 1 Year Change | -24.19% |
| 33 Year Change | 1.95% |
| 5 Year Change | -18.05% |
| Change since IPO | -17.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603351 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | -0.7% | 1.4% | 0.4% |
| 1Y | -24.2% | -22.6% | -17.8% |
Return vs Industry: 603351 underperformed the CN Chemicals industry which returned -22.6% over the past year.
Return vs Market: 603351 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 603351 volatility | |
|---|---|
| 603351 Average Weekly Movement | 5.4% |
| Chemicals Industry Average Movement | 7.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 603351's share price has been volatile over the past 3 months.
Volatility Over Time: 603351's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 673 | Renrong Wu | www.well-js.com |
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical auxiliary materials in China. Its pharmaceutical materials include excipients for injectables and non-injectables.
Nanjing Well Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 603351 fundamental statistics | |
|---|---|
| Market cap | CN¥2.76b |
| Earnings (TTM) | CN¥120.49m |
| Revenue (TTM) | CN¥1.24b |
22.8x
P/E Ratio2.2x
P/S RatioIs 603351 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603351 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.24b |
| Cost of Revenue | CN¥915.10m |
| Gross Profit | CN¥324.13m |
| Other Expenses | CN¥203.63m |
| Earnings | CN¥120.49m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 26.16% |
| Net Profit Margin | 9.72% |
| Debt/Equity Ratio | 27.4% |
How did 603351 perform over the long term?
See historical performance and comparison